24188-80-5

Usage

Uses

Due to the limited information available on the practical uses or applications of 1-Chloro-7-methylisoquinoline in the scientific or industrial sector, it is not possible to provide a detailed list of its applications. However, given its chemical structure and classification, it may have potential applications in the following areas:
Used in Pharmaceutical Research:
1-Chloro-7-methylisoquinoline could be used as a chemical intermediate or building block in the synthesis of various pharmaceutical compounds, particularly those targeting the central nervous system or other biological processes involving isoquinoline-based molecules.
Used in Chemical Synthesis:
As a member of the isoquinoline and derivatives class, 1-Chloro-7-methylisoquinoline may be utilized in the synthesis of other complex organic compounds, potentially serving as a key component in the development of new materials or chemical products.
Used in Academic Research:
1-Chloro-7-methylisoquinoline might be employed in academic research settings to study its chemical properties, reactivity, or potential interactions with other molecules, contributing to the broader understanding of isoquinoline chemistry and its applications.

InChI:InChI=1/C10H8ClN/c1-7-2-3-8-4-5-12-10(11)9(8)6-7/h2-6H,1H3

Upstream product

• 26829-47-0 7-methylisoquinolin-1(2H)-one 
• 26829-47-0 7-methyl-isoquinolin-1-ol 
• 10025-87-3 trichlorophosphate 

Downstream Products

• 950768-73-7 benzhydrylidene-(7-methyl-isoquinolin-1-yl)-amine 
• 209285-92-7 7-bromomethyl-1-chloro-isoquinoline 
• 54004-38-5 7-methyl isoquinoline 

Relevant academic research and scientific papers

Hepatitis C Virus Inhibitors

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

PYRIDINES AND PYRIDINE N-OXIDES AS MODULATORS OF THROMBIN

The present invention describes compounds of Formula I: wherein W, X, Y, Z, and Q are defined herein, or a pharmaceutically acceptable salt thereof, for the prophylaxis, or treatment of diseases and conditions related to thrombin activity in a mammal.

HEPATITIS C VIRUS INHIBITORS

Hepatitis C virus inhibitors are disclosed having the general formula:(I) wherein R1, R2, R3, R', B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds toinhibit HCV are also disclosed.

Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds

The compounds of formula I herein exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, for treating a patient suffering from, or subject to, a physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

Aminoisoquinolines: Design and synthesis of an orally active benzamidine isostere for the inhibition of factor Xa.

The design, synthesis and SAR of sulfonamidopyrrolidinone fXa inhibitors incorporating a new benzamidine isostere, namely aminoisoquinolines, is described. These inhibitors have higher Caco-2 cell permeability than comparable benzamidines and attain higher levels of exposure upon oral dosing. The most potent member 14b (fXa Ki=6 nM) is selective against other serine proteasesof interest (>600 fold).